The Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz Stimulates Replication of Human Immunodeficiency Virus Type 1 Harboring Certain Non-nucleoside Resistance Mutations

Eitemau Tebyg

• Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz
  gan: Calvo, Rosario, et al.
  Cyhoeddwyd: (2002)
• The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys,3) that correlate with reductions in replication efficiency
  gan: Wang, J., et al.
  Cyhoeddwyd: (2006)
• The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz
  gan: Clarke, Susan M, et al.
  Cyhoeddwyd: (2001)
• Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis
  gan: Gwag, Taesik, et al.
  Cyhoeddwyd: (2019)
• Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells
  gan: Jamaluddin, Md Saha, et al.
  Cyhoeddwyd: (2009)